Muvalaplin: Breakthrough Lipoprotein (a) Drug Successfully Completes Phase II Clinical Trials

Muvalaplin: A Breakthrough in Cholesterol Blockage Control

Significant Reduction in Lipoprotein (a)

The highly anticipated cholesterol-blocking medication Muvalaplin has shown the potential to reduce lipoprotein (a) levels by as much as 85% within a twelve-week timeframe. In a report from June, we highlighted the promising phase I clinical trial results. Recently, in January, researchers from the Victorian Heart Institute, led by Dr. John H. Krege, announced in a JAMA research article that Muvalaplin has successfully progressed to the next phase of clinical evaluation. This article reviews the drug’s performance against lipoprotein (a) in phase II clinical trials and provides background information on Muvalaplin and lipoprotein (a).

A Global Collaborative Effort

Australian researchers from Monash University partnered with an international network of clinicians to conduct a randomized, double-blind, placebo-controlled clinical trial to assess Muvalaplin’s efficacy. The trial involved 233 participants aged 40 and older, all of whom had serum lipoprotein (a) concentrations of 175 nmol/L or higher. These participants were recruited from 43 centers worldwide, including Australia, Brazil, China, Germany, Hungary, Japan, the Netherlands, and the United States. All participants had a history of type 2 diabetes, coronary artery disease, ischaemic stroke, peripheral arterial disease, or familial hypercholesterolaemia, placing them at increased risk for cardiovascular events. The trial’s diverse geographic scope allowed researchers to evaluate the drug’s effectiveness across various genetic backgrounds, diets, and healthcare approaches.

Clinical Trial Design

Randomized, Double-Blind, Placebo-Controlled Structure

Participants were randomly assigned to receive a twelve-week regimen of oral Muvalaplin at doses of 10 mg (34 participants), 60 mg (63 participants), or 240 mg (68 participants), or a placebo (67 participants). To ensure objective results, neither the doctors nor the patients were aware of the assigned medication. The trial aimed to investigate whether a dose-dependent effect existed and to monitor any potential side effects associated with higher dosages.

Every four weeks, the participants underwent blood tests to assess changes in their lipoprotein (a) levels in response to the treatment. Researchers collected data to track how lipoprotein (a) concentrations shifted over the twelve weeks, including whether levels decreased below 125 nmol/L, the changes in apolipoprotein B and hs-CRP levels, and any adverse effects or cardiovascular incidents experienced during the trial.

Results: Lipoprotein (a) Levels Decline

Upon completing the twelve-week study, researchers analyzed the blood test results. While the placebo group experienced negligible changes in lipoprotein (a) levels (-0.5% over three months), the Muvalaplin groups demonstrated substantial reductions. Participants taking 10 mg saw a 47.4% decrease, while those on 60 mg and 240 mg experienced reductions of up to 81.6% and 85.7%, respectively. Notably, the cholesterol levels in the drug treatment groups continued to decline at each testing interval. Initial average lipoprotein levels were 216.8 nmol/L, but by the end of the trial, 13 participants (38.9%) in the 10 mg group, 49 (81.9%) in the 60 mg group, and 53 (77.4%) in the 240 mg group achieved levels below 125 nmol/L. In contrast, only 2 participants (3.6%) in the placebo group reached this threshold.

Safety and Tolerability

Similar Adverse Events Across Groups

Participants taking Muvalaplin reported side effects at rates comparable to those in the placebo group. Interestingly, the placebo group experienced a higher incidence of serious adverse events than those receiving Muvalaplin. These findings suggest that, at least over the twelve-week period, the drug is well-tolerated without significant side effects.

Future Directions

While these results are promising, the trial’s duration was limited to twelve weeks. Phase III clinical trials for Muvalaplin are essential to determine its long-term effectiveness in lowering lipoprotein (a). Given the lack of widely available treatments for elevated lipoprotein (a), ongoing trials will also provide crucial insights into the role of lipoprotein (a) in cardiovascular disease and the extent of its impact.

Nicholls SJ, Ni W, Rhodes GM, et al. Oral Muvalaplin for Lowering of Lipoprotein (a): A Randomized Clinical Trial. JAMA. 2025;333(3):222–231. doi:10.1001/jama.2024.24017.